BIOMAT Database Logo BIOMAT Database Logo

[Interleukin-1 and interleukin-2]. 1990

D Uhl

UI MeSH Term Description Entries
D007239 Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases. Infection,Infection and Infestation,Infections and Infestations,Infestation and Infection,Infestations and Infections
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D Uhl
Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis.
July 1990, Arthritis and rheumatism,
D Uhl
[Prospects for cancer immunotherapy using interleukin-1(IL-1) and interleukin-2(IL-2)].
January 1983, Nihon rinsho. Japanese journal of clinical medicine,
D Uhl
[Decreased interleukin-1 and interleukin-2 production after splenectomy].
April 1994, Harefuah,
D Uhl
Interleukin 2/interleukin 2 receptor system in type 1 diabetes.
January 1989, Diabetes research and clinical practice,
D Uhl
[The measurement of interleukin 1 (IL 1) and interleukin 2 (IL 2) employing the MTT assay].
November 1985, Rinsho byori. The Japanese journal of clinical pathology,
D Uhl
Interleukin-2 augmentation of interleukin-1 and prostaglandin E2 production.
May 1989, Journal of leukocyte biology,
D Uhl
Enhancement of interleukin 1 and interleukin 2 releases by ubenimex.
March 1987, The Journal of antibiotics,
D Uhl
Interleukin-1 and interleukin-2 in chronic type B hepatitis.
April 1988, Gastroenterology,
D Uhl
[Quantitative bioassay of human interleukin 1 and interleukin 2 activities].
April 1985, Rinsho byori. The Japanese journal of clinical pathology,
D Uhl
[Changes in interleukin-1 and interleukin-2 in scalded rats].
September 1989, Zhonghua zheng xing shao shang wai ke za zhi = Zhonghua zheng xing shao shang waikf [i.e. waike] zazhi = Chinese journal of plastic surgery and burns,
Copied contents to your clipboard!